Evidence map›Paper›PMID 29957723›Full record

Trial reportAIDS (London, England)2018

Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results.

Elizabeth T Montgomery, Jonathan Stadler, Sarita Naidoo, Ariana W K Katz, Nicole Laborde, Morgan Garcia, Krishnaveni Reddy, Leila E Mansoor, Juliane Etima, Chifundo Zimba and 2 more

Registry-linked trialAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph

Trial report in AIDS (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02702895 (Assessment of ASPIRE and HOPE Adherence), which is not on this map. Cited by 36 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 5 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02702895 completednot on this map

Assessment of ASPIRE and HOPE Adherence

TypeobservationalSponsorMicrobicide Trials NetworkRan2016 to 2019Enrolled302ConditionsHIV PreventionArmsIn-depth Interview (IDIs) or Focus Group Discussion (FGD)
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 5 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 3 countries.

Elizabeth T MontgomeryWomen's Global Health Imperative, RTI International, San Francisco, California, USA.
Jonathan StadlerDepartment of Anthropology and Development Studies, University of Johannesburg, Johannesburg.
Sarita NaidooHIV Prevention Research Unit, South African Medical Research Council, Durban, South Africa.
Ariana W K KatzWomen's Global Health Imperative, RTI International, San Francisco, California, USA.
Nicole LabordeWomen's Global Health Imperative, RTI International, San Francisco, California, USA.
Morgan GarciaFHI 360, Durham, North Carolina, USA.
Krishnaveni ReddyWits Reproductive Health and HIV Institute, University of the Witwatersrand, School of Clinical Medicine, Johannesburg.
Leila E MansoorCentre for the AIDS Programme of Research in South African (CAPRISA), Durban, South Africa.
Juliane EtimaMakerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda.
Chifundo ZimbaUNC Project-Malawi, Lilongwe, Malawi.
Miria ChitukutaUniversity of Zimbabwe College of Health Sciences Clinical Trials Unit (UZCHS-CTU), Harare, Zimbabwe.
Lydia Soto-TorresDivision of AIDS, NIH, Bethesda, Maryland, USA.
RTI International · USCentre for the AIDS Programme of Research in South Africa · ZAFamily Health International 360 · USMUJHU Research Collaboration · UGOffice of AIDS Research · USSouth African Medical Research Council · ZAUniversity of Johannesburg · ZAUniversity of the Witwatersrand · ZA

Funding

Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
Microbicide Trials NetworkU01AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2006 to 2010
$77.0M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
University of KwaZulu-Natal - CAPRISA HIV/AIDS Clinical Trials UnitUM1AI069469 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI QUARRAISHA ABDOOL KARIM · 2012 to 2026
$36.4M
The Johns Hopkins University - Uganda Clinical Trials UnitUM1AI069530 · NIAID · JOHNS HOPKINS UNIVERSITY · PI MARY Glenn Fowler, Philippa Musoke · 2012 to 2026
$34.8M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
NIAID NIH HHS U01 AI068633NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI069469NIAID NIH HHS UM1 AI069530NIAID NIH HHS UM1 AI106707
6 · The paper itself

Abstract

OBJECTIVE(S): MTN-020/ASPIRE trial and IPM-027/Ring Study recently proved the dapivirine vaginal ring was safe and effective with consistent use. To optimize the ring's impact, the barriers and facilitators to ring adherence must be understood and addressed.

methodsFormer ASPIRE participants were stratified by age group (18-21; 22-45) and randomly selected at seven sites in Malawi, South Africa, Uganda and Zimbabwe, 12-17 months after trial exit. Using in-depth interviews or focus group discussions, ring use barriers were explored using structured guides and visual tools including individual-level depictions of dapivirine levels detected in plasma and returned rings.

resultsA total of 187 were enrolled; 37% were 18-21 years when they began ASPIRE. Most (75%) had drug-level results, suggesting inconsistent ring use throughout ASPIRE. Participants viewed themselves as adherent, while simultaneously describing regular instances and reasons for ring removal (e.g. for sex or menses). Less adherent women reported fears that partners would oppose the ring or feel it during sex. High adherers expressed altruistic motivations for ring use. Women of all ages attributed young women's nonadherence to their tendency to be less 'serious' about the future, HIV prevention and the study; motivated predominantly by benefits; more fearful of fertility-related consequences; and to having less relationship control.

conclusionWhen presented with objective adherence data, participants provided reasons for intermittent ring use, while simultaneously portraying themselves as consistent ring users. Further research is needed to understand how women could use the ring in a way that fits into the context of their relationships and their lives while still conferring adequate HIV prophylaxis.

Indexed as

Contraceptive Devices, FemaleAdolescentAdultAfricaAnti-HIV AgentsDouble-Blind MethodHIV InfectionsHumansInterviews as TopicMiddle AgedPatient Acceptance of Health CarePatient CompliancePre-Exposure ProphylaxisPyrimidinesYoung AdultAnti-HIV AgentsDapivirinePyrimidines

Identifiers

PMID29957723
PMCPMC6230508
OpenAlexW2803101737

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.